AI Automated Translation.

Font Size

Share

Adel CEO Yoon Seung-yong: "Timing of Sanofi's Phase 1b entry undetermined… Confident in follow-on deals"

Adel CEO Yoon Seung-yong: "Timing of Sanofi's Phase 1b entry undetermined… Confident in follow-on deals"

Adel CEO Yoon Seung-yong introduces the company's growth strategy at an IPO (initial public offering) briefing held on the 18th in Seoul Yeouido. /Photo=Adel
Adel CEO Yoon Seung-yong introduces the company's growth strategy at an IPO (initial public offering) briefing held on the 18th in Seoul Yeouido. /Photo=Adel

Adel expressed confidence in a follow-up global technology transfer for its lead pipeline, the Alzheimer's disease treatment 'ADEL-Y01.' The company emphasized that it will leap forward as a global central nervous system (CNS) new drug development firm based on its repeated commercialization track record.

Adel CEO Yoon Seung-yong stated this while introducing the company's growth strategy at an IPO (initial public offering) briefing held on the 18th in Seoul Yeouido. Adel is currently proceeding with the listing process on the KOSDAQ market through a technology-based special listing.

"We have demonstrated Adel's new drug research capabilities with ADEL-Y01," said CEO Yoon. "Based on our experience dealing with global big pharma (major pharmaceutical companies), we will continue to pursue follow-on technology transfers."

Adel is a biotech (biotechnology company) established in 2016 through a spin-off from Seoul Asan Hospital, Ulsan University College of Medicine. The company primarily researches treatments for degenerative brain diseases, including Alzheimer's disease. Based on precision antibody technology that selectively targets only the pathologically specific forms causing the disease while preserving the physiological functions of normal proteins, Adel has discovered multiple new drug pipelines.

Adel gained attention in December last year by transferring the technology for ADEL-Y01 to global pharmaceutical company Sanofi. The total contract value of this deal is $1.04 billion (approximately 1.3841 trillion won). The non-refundable upfront payment is $80 million (approximately 106.5 billion won). The contract fee and milestone payments (royalties) received from the ADEL-Y01 technology transfer are shared among Adel, its joint development partner OscoTech, and Ulsan University College of Medicine/Asan Hospital. OscoTech receives 47% of the total, and 10% of the remaining amount received by Adel is allocated to Ulsan University College of Medicine/Asan Hospital.

Adel generated revenue of 62.1 billion won last year, a figure that reflects the upfront payment from the ADEL-Y01 technology transfer contract.

Adel completed Phase 1a clinical trials for ADEL-Y01 before transferring the technology to Sanofi. Subsequent clinical trials are led by Sanofi. The drug has not yet entered Phase 1b. Regarding this, CEO Yoon stated, "Due to confidentiality clauses in the contract, we cannot disclose specific clinical strategies for ADEL-Y01," adding, "We cannot yet specify the timing of entry into Phase 1b." He further noted, "Typically, it takes one to two years to re-enter a clinical trial," and said, "We are continuing practical work with Sanofi to enter Phase 1b."

Adel's ADEL-Y01 is an antibody therapy targeting the 'Tau' protein, a core pathogenic factor closely associated with cognitive decline in Alzheimer's disease. While typical tau antibodies target entire specific tau regions, ADEL-Y01 possesses differentiated characteristics by selectively recognizing the 'acK280' modification, which plays a critical role in the aggregation and propagation of tau pathology.

Adel is pursuing technology transfers for its follow-up Alzheimer's disease treatment pipelines, including 'ADEL-Y04' and 'ADEL-Y03.' Both are currently in the preclinical stage. In particular, the company aims to sign a global technology transfer contract for ADEL-Y04 next year. CEO Yoon stated, "We are continuing negotiations with global pharmaceutical companies regarding the technology transfer of ADEL-Y04."

Adel's desired IPO price band is 18,000 to 25,000 won. Based on this band, the offering size is 39.1 billion to 54.3 billion won, and the corporate valuation (including stock options) is 407.9 billion to 566.5 billion won. The absence of a pipeline in Phase 2 or later stages could be cited as a weakness during the offering process. Conversely, the company's experience with large-scale technology transfers with global big pharma is considered attractive. It is observed that the success of the IPO will depend on evaluations regarding the clinical progress of ADEL-Y01 and the potential for technology transfers of follow-up pipelines.

Adel conducted demand indication from institutional investors through today and will accept housing subscription from general investors on the 23rd and 24th. The lead underwriters are Samsung Securities and Mirae Asset Securities.

"Adel has secured multiple new drug pipelines based on its understanding of the core pathogenic mechanisms of Alzheimer's disease," said CEO Yoon. "We will expand our R&D capabilities, which have been validated through global technology transfers, to follow-up pipelines and create repeated technology transfer results."

"This article was translated using AI and may differ slightly from the original."